Get the Stockscreener App
55.22
0.19%
0.05
Exact Sciences Corp stock is traded at $55.22, with a volume of 845.20K.
It is up +0.19% in the last 24 hours and up +3.65% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$55.17
Open:
$55.02
24h Volume:
845.20K
Relative Volume:
0.31
Market Cap:
$10.43B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-10.02
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
-4.07%
1M Performance:
+3.65%
6M Performance:
-11.72%
1Y Performance:
+21.35%
1-Day Range:
$54.41
$55.59
1-Week Range:
$54.35
$57.43
52-Week Range:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
55.29 | 10.96B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
400.79 | 151.80B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
193.08 | 135.27B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
524.31 | 41.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.49 | 31.50B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
148.33 | 24.01B | 15.50B | 1.33B | 2.16B | 7.34 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio? - Yahoo Finance
Global Colorectal Cancer Screening and Diagnostics Market to Reach $46.1 Billion by 2029 - WV News
Epigenetics Market Anticipated to Achieve 11.8% CAGR - GlobeNewswire Inc.
Exact Sciences at William Blair Conference: Vision for Cancer Eradication - Investing.com
Transcript : Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08 - marketscreener.com
Exact Sciences (EXAS): Company Profile, Stock Price, News, Rankings - Fortune
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap - Business Wire
Exact Sciences Clears Technical Benchmark, Hitting 80-Plus RS Rating - inkl
Exact Sciences Announces Expanded Clinical Validation Of Oncodetect Test And Molecular Residual Disease Innovation Roadmap - marketscreener.com
Exact Sciences to present new positive data on Oncodetect in colorectal cancer - TipRanks
Exact Sciences (EXAS) Unveils Advanced MRD Test Data for Colorectal Cancer | EXAS Stock News - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Onc - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap | EXAS Stock News - GuruFocus
Exact Sciences management to meet with Oppenheimer - TipRanks
Exact Sciences to Participate in June Investor Conference | EXAS Stock News - GuruFocus
Exact Sciences to Participate in June Investor Conference - The Joplin Globe
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 2,099 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Highlights Innovations in Early Cancer Detection - GuruFocus
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025 - Business Wire
WisBusiness: the Show with Kevin Boggs of Medical College of Wisconsin - WisBusiness
Exact Sciences Corporation (EXAS) Slid on Fear of Competition - Insider Monkey
Comerica Bank Lowers Position in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
EXAS Q1 Earnings Call: Outperformance Driven by Commercial Execution, New Products, and Margin Expansion - Yahoo Finance
10 High PE Stocks Insiders Are Buying - Insider Monkey
Exact Sciences at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years - AOL.com
Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Exact Sciences Earns 2025 Great Place To Work® Certification™ - Business Wire
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Exact Sciences Announces First-Quarter 2025 Results - ADVFN
Exact Sciences (NASDAQ:EXAS) Price Target Raised to $72.00 - Defense World
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report - Yahoo
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp Reports Strong Start to 2025 - TipRanks
Exact Sciences (EXAS) Target Price Raised by Barclays to $75 | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Price Target Raised by RBC Capital | EXAS Stock News - GuruFocus
Exact Sciences: Q1 Earnings Snapshot - GMToday.com
Lobbying Update: $470,000 of EXACT SCIENCES lobbying was just disclosed - Nasdaq
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - Barchart.com
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - Benzinga
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS S - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS Stock News - GuruFocus
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance - Benzinga
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analys - GuruFocus
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating - marketscreener.com
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analyst | EXAS Stock News - GuruFocus
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exact Sciences Corp Stock (EXAS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Conroy Kevin T | President and CEO |
Mar 07 '25 |
Option Exercise |
22.38 |
66,723 |
1,493,261 |
1,203,269 |
| Herriott James | SVP, General Counsel & Sec |
Feb 28 '25 |
Option Exercise |
0.00 |
4,265 |
0 |
16,339 |
| Conroy Kevin T | President and CEO |
Feb 28 '25 |
Option Exercise |
0.00 |
40,310 |
0 |
1,146,965 |
| Baranick Brian | EVP, GM, Precision Oncology |
Feb 28 '25 |
Option Exercise |
0.00 |
9,673 |
0 |
25,106 |
| ORVILLE JACOB A | EVP, GM, Screening |
Feb 28 '25 |
Option Exercise |
0.00 |
9,673 |
0 |
27,728 |
| Condella Sarah | EVP, Human Resources |
Feb 28 '25 |
Option Exercise |
0.00 |
7,738 |
0 |
84,399 |
| Condella Sarah | EVP, Human Resources |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
80,297 |
| Baranick Brian | EVP, GM, Precision Oncology |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
19,841 |
| Herriott James | SVP, General Counsel & Sec |
Feb 25 '25 |
Option Exercise |
0.00 |
1,647 |
0 |
13,738 |
| ORVILLE JACOB A | EVP, GM, Screening |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
22,136 |
0.25%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):